The efficacy of lenalidomide-induced CK1α degradation in other cell lines, including THP-1 monocytes, HCT116 colorectal cancer, A549 lung adenocarcinoma, DLD-1 colorectal cancer, PC-3 prostate cancer, and HaCaT keratinocyte cell lines were more variable with the most substantial CK1α degradation observed in HCT116, DLD-1, and HaCaT cells (Fig 1B). The gene discussed is CSNK1A1; the disease is Familial prostate cancer.